A phase Ib study of a pooled synthetic long peptide mutant KRAS vaccine combined with balstilimab/botensilimab in metastatic pancreatic cancer and metastatic MMR-proficient colorectal cancer in the maintenance setting.

A record is what was published and who pointed at it. The text of the post is not held here: read it at the source, or at its Wayback capture.

First cited

—

Most recent

—

Rank this month

not ranked

External links

0

Words captured

441